Avant Technologies Inc

2025-03-26 01:58:55

(MENAFN- Baystreet) 09:44 AM EST - Avant Technologies Inc : Along with its partner, Ainnova Tech, Inc., today announced that the Company has started designing its clinical trial protocol ahead of a pre-submission meeting with the U.S. Food and Drug Administration (FDA). The pre-submission meeting is to request guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy, and Ainnova's clinical trial will culminate in the submission of an FDA 510(k) to obtain clearance from the regulatory agency to market its technology. Avant Technologies Inc shares O are trading up one cent at $0.50.

Full Press Release:

MENAFN26032025000212011056ID1109357472

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.